Biomarkers
Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS
Environmental Research 2020 November 13 [Link] Hailing Xia, Lingfang Feng, Lijun Lin, Zhaoqiang Jiang, Junqiang Chen, Wei Shi, Shibo Ying, Min Yu, Li Ju, Lijin Zhu, Li Shi, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive cancer linked to asbestos exposure. Its poor prognosis makes early diagnosis extremely important, which would provide…
Read MoreA liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
EBioMedicine 2020 October 9 [Link] Bill T V Duong, Licun Wu, Brenda J Green, Fatemeh Bavaghar-Zaeimi, Zongjie Wang, Mahmoud Labib, Yuxiao Zhou, Fernando J P Cantu, Thurgaa Jeganathan, Sandra Popescu, Jennifer Pantea, Marc de Perrot, Shana O Kelley Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer related to asbestos exposure. Early diagnosis is…
Read MoreTargeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
Pharmaceuticals 2020 October 2 [Link] Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Diana Cao, Ingrid J G Burvenich, Angela Rigopoulos, Edward B Reilly, Thomas John, Andrew M Scott Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a…
Read MoreImmunotherapy for mesothelioma: rationale and new approaches
Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…
Read MoreAssociation of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The Lancet Oncology 2020 October [Link] Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller Jr, Antoine Italiano, Steven Kao, Sarina A Piha-Paul, Jean-Pierre Delord, Robert R McWilliams, David A Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung-Jue…
Read MoreVerification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 30 [Link] Ferdinando Cerciello, Meena Choi, Sara L Sinicropi-Yao, Katie Lomeo, Joseph M Amann, Emanuela Felley-Bosco, Rolf A Stahel, Bruce W S Robinson, Jenette Creaney, Harvey I Pass, Olga Vitek, David P Carbone Abstract Background: We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection…
Read MoreNew vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction
Life Sciences 2020 July 22 [Link] Manav Gandhi, Sujit Nair Abstract Malignant mesothelioma (MM) is a cancer of the mesothelial lining of the pleura, peritoneum, pericardium and testes. The most common form is asbestos-linked MM that is etiologically linked to repeated asbestos exposure with a long latency period, although non-asbestos MM has also been reported.…
Read MoreMesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 22 [Link] Harvey I Pass, Marjan Alimi, Michele Carbone, Haining Yang, Chandra M Goparaju Abstract Background: Malignant Pleural Mesothelioma (MPM) is an asbestos related neoplasm which can only be treated successfully when correctly diagnosed and treated in early stages. The asbestos exposed population serves as a high risk…
Read MoreVerification of a blood based targeted proteomics signature for malignant pleural mesothelioma
Cancer Epidemiol Biomarkers, July 30, 2020 (Epub ahead of print) [Link] Ferdinando Cerciello, et.al. Abstract Background: We have verified a mass spectrometry (MS) based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood. Methods: A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent…
Read MoreTreatment response monitoring in patients with advanced malignancies using cell-free SHOX2 and SEPT9 DNA methylation in blood: An observational prospective study.
The Journal of Molecular Diagnostics 2020 April 30 [Link] de Vos L, Jung M, Koerber RM, Bawden EG, Holderried TAW, Dietrich J, Bootz F, Brossart P, Kristiansen G, Dietrich D Abstract Patients with incurable cancer usually receive palliative treatment with significant toxicity and limited efficacy. Methylation analysis of circulating cell-free DNA in blood from cancer…
Read More